Investigative Medicine Division

We aim to rapidly translate innovative science into patient benefit across a range of disease areas. From molecular biology and target discovery, through to interventional medicine and informing policy, we bring together researchers in a diverse range of specialties including acute stroke, dementia and immunology.

Head of Division

Alison Simmons

Director of the MRC Translational Immune Discovery Unit

alison.simmons@imm.ox.ac.uk

Our Research

We aim to translate innovative science into patient benefit across a range of specialities, with a specific focus on immunology, stroke and non-invasive imaging combined with artificial intelligence/big data.

Goblet cell differentiation subgroups in colorectal cancer.
Journal article

Abdullayeva G. et al, (2024), Proc Natl Acad Sci U S A, 121
Temporal changes in erythroid progenitors in critically ill patients: a prospective cohort study
Journal article

Scott C. et al, (2024), Haematologica
Salmonella Typhimurium screen identifies shifts in mixed-acid fermentation during gut colonization.
Journal article

Nguyen BD. et al, (2024), Cell host & microbe, 32, 1758 - 1773.e4
Development of a recombinant non-replicating Newcastle disease virus.
Journal article

Cheow P-S. et al, (2024), Avian Pathol, 1 - 9
Safety in spinal surgery—Empowering clinicians to report concerns in motor function
Journal article

Burrows J. et al, (2024), Journal of Advanced Nursing

COVID-19 research

Structural model of the mosaic-8 RBD-mi3 nanoparticle design.

Fan et al., (in press) https://www.biorxiv.org/content/10.1101/2022.06.28.497989v1
Cohen et al., (2022) Science https://www.science.org/doi/10.1126/science.abq0839

Novel all-in-one vaccine developed to tackle future coronavirus threats

6 July 2022

Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.

A T-cell is shown attacking a SARS-CoV-2 virus.

Strong cytotoxic T cell responses to an internal viral component are associated with mild COVID-19 disease

1 December 2021

Study from the Dong Group reveals key differences in the adaptive immune responses of patients with mild vs. severe COVID-19, highlighting a potential new vaccine target.